Schimmel M, Utiger R D
Clin Endocrinol (Oxf). 1977 Apr;6(4):329-32. doi: 10.1111/j.1365-2265.1977.tb02018.x.
Patients treated with inorganic iodide weeks to years following 131I therapy for hyperthyroidism do not adapt to its antithyroid effect. To determine whether such adaptation occurs soon after 131I therapy, serum thyroxine (T4) and triiodothyronine (T3) concentrations were measured daily for 9-14 days following 131I therapy in seventeen hyperthyroid patients. Nine patients received 150 mg KI daily starting 48 h after 131I administration; eight received only 131I. Serum T4 and T3 concentrations did not change significantly in the patients who received only 131I. In the patients who received 131I and KI, serum T4 and T3 concentrations fell promptly, reaching nadir values 2-10 days after initiation of iodide, and then increased despite continuation of KI therapy. The mean maximal fall in serum T4 was 34% and in serum T3 42%. These results show that "escape" from the acute anti-thyroid effect of iodide occurs when it is given immediately after 131I therapy, thus limiting the utility of iodide as a therapeutic agent at this time.
在接受放射性碘(131I)治疗甲亢数周或数年之后使用无机碘治疗的患者,无法适应其抗甲状腺作用。为了确定这种适应性是否在131I治疗后很快出现,对17例甲亢患者在131I治疗后的9 - 14天内每天测量血清甲状腺素(T4)和三碘甲状腺原氨酸(T3)浓度。9例患者在131I给药48小时后开始每天服用150毫克碘化钾(KI);8例仅接受131I治疗。仅接受131I治疗的患者血清T4和T3浓度无显著变化。接受131I和KI治疗的患者,血清T4和T3浓度迅速下降,在开始服用碘化物后的2 - 10天达到最低点,然后尽管继续KI治疗仍有所上升。血清T4的平均最大降幅为34%,血清T3为42%。这些结果表明,在131I治疗后立即给予碘化物时,会出现对碘化物急性抗甲状腺作用的“逃逸”现象,从而限制了此时碘化物作为治疗药物的效用。